AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 81 min read$NRXS

Henrichs Timothy Robert purchased $9K of NRXS

Henrichs Timothy Robert (Chief Financial Officer) purchased 1,937 shares of Neuraxis, INC (NRXS) at $4.84 on 2026-10-08.

Original reporting
SEC EDGAR · Henrichs Timothy Robert
Published Oct 8, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NRXS
Bullish
high confidence
Mentioned
$NRXS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRXSBullishLow
01

Why it matters

While the dollar amount is modest, insider buying can be interpreted as a positive signal, though the effect on price is likely limited.

02

Market read

Primary insider purchase filing; low materiality but provides a fresh data point for traders monitoring insider activity.

03

What to watch

Potential upcoming clinical milestones or financing needs not disclosed could amplify the significance of insider buying.

Relevance 4/10Novelty 4/10Timing: same day filing

Background

SEC Form 4 filing discloses an insider purchase by Neuraxis's CFO.

Company-level read

Ticker impact

$NRXSBullishHigh confidence
Context

CFO Timothy Robert Henrichs bought 1,937 shares of Neuraxis at $4.84 each, increasing his stake to 9,530 shares.

Expected impact

modest upward pressure as the market prices in insider confidence

Evidence & confidence

Form 4 filing is a primary source; the purchase is small but represents a direct buy by a senior executive, which traders often view as a bullish signal.

Market effects

Sector

Minimal impact on the biotech sector; the transaction is company‑specific.

Regional

No discernible regional effect.

Global

Limited to investors tracking insider activity in small‑cap biotech stocks.

Counterpoint

What could challenge this read

The purchase is too small to move the stock and may be routine portfolio rebalancing.

Key entities

  • company
    Neuraxis, Inc.

    Biotech firm listed under ticker NRXS.

  • person
    Timothy Robert Henrichs

    Chief Financial Officer of Neuraxis.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NRXS insider trading history →

Related articles

SEP 16
$NRXSHighAI 8/10

NeurAxis Expands PENFS Coverage By 18 Million Lives As IB-Stim Adoption Grows; Stock Up

NeurAxis (NRXS) announced that a major national insurer expanded coverage for its PENFS therapy, adding 18 million members, bringing total coverage to 120 million. The company's IB-Stim device is FDA-cleared for pediatric abdominal pain. CEO Brian Carrico highlighted growth acceleration and plans to pursue additional insurers. NRXS stock is up 21.77% to $6.94.

rttnews.com2 min
SEP 16
$NRXSHigh

NeurAxis secures major insurer coverage for IB-Stim device

NeurAxis (NRXS) announced a major national health insurer will cover its IB-Stim device for treating abdominal pain in patients aged 8+. The coverage applies to 18M members across multiple states. The FDA-cleared device is a non-invasive neuromodulation technology. NeurAxis aims to secure coverage from more insurers and is conducting additional clinical trials. The company did not disclose the insurer's name or provide financial projections.

investing.com2 min
SEP 16
$NRXSMed

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

NeurAxis (NRXS) announced a new medical policy coverage from a major national health insurer for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, expanding access to 18 million members. IB-Stim is FDA-cleared for treating functional abdominal pain in children and adults. The company aims to broaden payer coverage and increase commercialization, citing a strong foundation and potential for revenue growth.

globenewswire.com2 min